Halozyme CEO Helen Torley sells $6.61m in shares

Halozyme Therapeutics CEO Helen Torley sold a total of $6.61 million worth of company shares over three trading days in early October 2026, executing trades under a pre-arranged Rule 10b5-1 plan. The sales occurred at weighted average prices ranging from $107.902 to $113.693 per share, with specific transactions on October 6, 7, and 8.

Torley disposed of 60,000 shares, reducing her direct holdings to 767,780 shares. Prior to these sales, she acquired the shares through the exercise of stock options granted in 2018, which were exercised at $18.41 per share. The company recently secured a $1.5 billion convertible notes offering and faced a patent infringement ruling against Merck & Co. in Europe, while H.C. Wainwright maintained a Buy rating with a $115 price target.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.